Biodesix (NASDAQ:BDSX) Issues Quarterly Earnings Results, Meets Estimates

Biodesix (NASDAQ:BDSX) posted its earnings results on Thursday. The company reported ($0.75) EPS for the quarter, meeting analysts’ consensus estimates of ($0.75), FiscalAI reports. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. The company had revenue of $24.04 million for the quarter, compared to analysts’ expectations of $27.49 million.

Here are the key takeaways from Biodesix’s conference call:

• Biodesix reported Q3 revenue of $24.0 million, up 10%, and diagnostic test volume up 24%, but results fell short of expectations. Management attributed the shortfall to fewer sales representatives than planned, weaker-than-expected primary-care seasonality and delayed development-services projects.
• The company lowered its 2026 revenue outlook to $101 million–$103 million, or about 15% growth at the midpoint. Management expects development-services revenue to remain near $1 million in Q4, with many projects shifting into 2027; it also said a higher mix of Nodify CDT tests is weighing on average revenue per test.
• Commercial capacity has improved to about 110 representatives, with a target of 115 by year-end. Management said October was its strongest month of new-physician acquisition this year and expects added sales capacity and improved forecasting to support a recovery, while noting new hires take time to ramp.
• Biodesix cited the CHEST lung-nodule management framework and early enterprise-wide integrations at two major health systems as support for broader use of its Nodify tests. These system-level rollouts could make adoption more scalable, though management cautioned that implementation takes time.
• The company is expanding beyond blood-based diagnostics with a radiomic lung-nodule test targeted for commercialization in 2028 and two MRD assay programs developed with Bio-Rad and Thermo Fisher. These initiatives broaden its longer-term opportunity, but remain in development.

Biodesix Stock Down 48.0%

NASDAQ BDSX traded down $9.53 on Friday, reaching $10.31. The company had a trading volume of 375,745 shares, compared to its average volume of 481,342. The firm has a 50-day moving average of $25.93 and a 200-day moving average of $18.90. The firm has a market capitalization of $108.83 million, a PE ratio of -3.25 and a beta of 0.65. Biodesix has a 1 year low of $5.26 and a 1 year high of $31.97. The company has a debt-to-equity ratio of 5.12, a current ratio of 2.85 and a quick ratio of 2.85.

Insider Activity

In related news, Director Jack Schuler acquired 15,000 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was bought at an average cost of $24.47 per share, with a total value of $367,050.00. Following the acquisition, the director directly owned 555,810 shares in the company, valued at approximately $13,600,670.70. The trade was a 2.77% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders purchased 42,600 shares of company stock valued at $1,033,062. Corporate insiders own 23.20% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on BDSX. TD Cowen reaffirmed a “buy” rating and set a $40.00 price objective (up from $30.00) on shares of Biodesix in a research report on Tuesday, October 13th. HC Wainwright reiterated a “buy” rating on shares of Biodesix in a research note on Thursday, October 22nd. Weiss Ratings raised shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 8th. Finally, Canaccord Genuity Group boosted their target price on shares of Biodesix from $27.00 to $35.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Biodesix presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.25.

Biodesix Company Profile

Biodesix, Inc is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of lung diseases, including lung cancer. The company combines proprietary molecular diagnostic technologies, clinical data, and artificial intelligence to help physicians assess disease risk and make more informed treatment decisions.

Its offerings include blood-based tests designed to help evaluate indeterminate pulmonary nodules, identify patients who may be at higher risk of lung cancer, and support treatment selection and monitoring.